Lupin, Zydus Life shares slide up to 7.5% after US Court blocks generic version of Myrbetriq over patent infringement

Lupin Ltd. and Zydus Lifesciences Ltd. shares fell sharply after a US court upheld Astellas Pharma's patent on Myrbetriq, blocking the companies from selling their generic versions. This ruling poses significant challenges to their US market strategies and has raised investor concerns.

Markets